Zika virus (ZIKV) caused unprecedented outbreaks in South America and the Caribbean in 2015-2016, leading primarily to a series of abnormalities in neonates termed congenital Zika syndrome. The threat of ZIKV reemergence has seen the development of multiple ZIKV vaccines that are at the preclinical stage or in early-stage clinical trials. Herein, we describe a pathway to the development of ZIKV vaccines generated using a baculovirus-insect cell expression system, which is widely applied for the manufacture of biologics for human use. Virus-like particle (VLP) vaccines comprising CprME and subviral particle (SVP) vaccines comprising prME were evaluated for their ability to mediate protection against ZIKV challenge in Ifnar1-/- mice. Initial attempts resulted in VLP and SVP vaccines that failed to present quaternary epitopes and did not provide effective protection. To improve the SVP vaccine, two modifications were introduced: firstly, an alanine to cysteine substitution (A264C) in the ...
| Authors | Abbo, SR; Yan, K; Geertsema, C; Hick, TAH; Altenburg, JJ; Nowee, G; van Toor, C; van Lent, JW; Nakayama, E; Tang, B; Metz, SW; Bhowmik, R; de Silva, AM; Prow, NA; Correia, R; Alves, PM; Roldão, A; Martens, DE; van Oers, MM; Suhrbier, A; Pijlman, GP |
|---|---|
| Journal | JOURNAL OF VIROLOGY |
| Pages | e0232224 |
| Volume | |
| Date | 27/03/2025 |
| Grant ID | |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1128/jvi.02322-24 |